您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2017, Vol. 55 ›› Issue (3): 100-106.doi: 10.6040/j.issn.1671-7554.0.2016.1471

• 临床医学 • 上一篇    下一篇

致癌蛋白CIP2A在乳腺导管上皮恶变中的作用及预测浸润性导管癌患者预后的能力

林家香1,郭子嘉2,苏鹏3,王晓1,郭雅欣4,吴晓娟1,相磊1,周志强1, 王妍1,崔秀杰1,潘爱凤1,郭成浩1   

  1. 1. 山东大学医学院病理学教研室, 山东 济南250012;2. 山东中医药大学第一临床医学院中医妇科, 山东 济南 250012;3. 山东大学齐鲁医院病理科, 山东 济南 250012;4. 山东大学公共卫生学院, 山东 济南 250012
  • 收稿日期:2016-11-09 出版日期:2017-03-10 发布日期:2017-03-10
  • 通讯作者: 郭成浩. E-mail:chenghaoguo@sdu.edu.cn E-mail:chenghaoguo@sdu.edu.cn
  • 基金资助:
    中国博士后科学基金(2014M560560);山东省自然科学基金(ZR2012HQ002)

The role of CIP2A in the transformation of breast ductal epithelium and prognosis of invasive breast cancer

LIN Jiaxiang1, GUO Zijia2, SU Peng3, WANG Xiao1, GUO Yaxin4, WU Xiaojuan1, XIANG Lei1, ZHOU Zhiqiang1, WANG Yan1, CUI Xiujie1, PAN Aifeng1, GUO Chenghao1   

  1. 1. Department of Pathology, School of Medicine, Shandong University, Jinan 250012, Shandong, China;
    2. Department of Gynecology of Chinese Medicine, First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250012, Shandong, China;
    3. Department of Pathology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    4. School of Public Health, Shandong University, Jinan 250012, Shandong, China
  • Received:2016-11-09 Online:2017-03-10 Published:2017-03-10

PDF (PC)

676

摘要： 目的 探讨蛋白磷酸酶2A的癌性抑制因子(CIP2A)在乳腺导管上皮的恶性转化过程中的作用及其预测浸润性导管癌患者预后的能力。 方法 收集乳腺正常导管上皮(正常对照)、普通型增生(UDH)、不典型增生(ADH)、导管内癌(DCIS)及浸润性导管癌(IDC)的石蜡标本322例,采用免疫组织化学染色法检测其中CIP2A的表达。通过χ2检验分析各组间CIP2A的表达差异,并验证CIP2A与DCIS及IDC患者临床病理学参数的关系。通过Kaplan-Meier生存分析及Cox比例风险回归模型分析CIP2A与IDC患者预后的关系。 结果 CIP2A在正常对照组、UDH组、ADH组、DCIS组及IDC组的表达率分别为6.66%、5.13%、6.66%、32.35%及32.45%。 CIP2A分别在UDH组与DCIS组、UDH组与IDC组的表达差异有统计学意义(P=0.004 3、P=0.004 0)。 CIP2A表达与DCIS患者的高组织学分级及高Ki67指数呈显著相关性(P均<0.05)。在IDC患者中,CIP2A表达与CerbB2(Her-2)阳性、高Ki67指数、高TNM分期及淋巴结转移呈显著相关性(P均<0.05)。CIP2A阳性患者5年无病生存率和总生存率显著降低,且CIP2A可以作为一种独立的预后因子预测IDC患者预后。 结论 CIP2A在乳腺导管上皮癌变过程中可能发挥重要作用。CIP2A有望用于监测导管上皮癌变,并预测IDC患者的预后。

关键词: 导管内癌, 浸润性导管癌, 普通型增生, 不典型增生, 癌性抑制因子, 预后, 蛋白磷酸酶2A

Abstract: Objective To explore the role of cancerous inhibitor of protein phosphatase 2A(CIP2A)in the malignant transformation of breast ductal epithelium and its association with the prognosis of breast ductal cancer. Methods Immunohistochemistry staining was used to detect CIP2A protein in 322 paraffin-embedded breast samples including normal breast duct, usual ductal hyperplasia(UDH), atypical ductal hyperplasia(ADH), ductal carcinoma in situ(DCIS)and invasive ductal carcinoma(IDC). Chi-square test was used to assess the difference of CIP2A expressions, and the correlation between CIP2A expression and the clinicopathologic characteristics. Kaplan-Meier method and Cox proportional hazard regression model were adopted to analyze the survival rate of patients. Results The expression rate 山 东 大 学 学 报 (医 学 版)55卷3期 -林家香,等.致癌蛋白CIP2A在乳腺导管上皮恶变中的作用及预测浸润性导管癌患者预后的能力 \=-of CIP2A in of normal tissue, UDH, ADH, DCIS and IDC was 6.66%, 5.13%, 6.66%, 32.35% and 32.45%, respectively. There was significant difference between UDH and DCIS groups, and UDH and IDC groups(P=0.004 3, P=0.004 0). Furthermore, CIP2A expression was closely associated with high histological grade and Ki67 index in DCIS samples(both P<0.05). In IDC patients, CIP2A expression was significantly correlated with CerbB2(Her-2)positive expression, high Ki67 index, high TNM stage and lymph node metastasis(all P<0.05). Patients with positive CIP2A expression exhibited significantly shortened 5-year disease-free and overall survival rate. CIP2A could be an independent prognostic indicator for IDC. Conclusion CIP2A plays a key role in the transition from proliferative lesions to ductal carcinoma. It holds the potential to monitor the malignant transformation of breast duct epithelium, and to guide the prognosis and personal treatment of patients with breast cancer.

Key words: Usual ductal hyperplasia, Atypical ductal hyperplasia, Cancerous inhibitor of protein phosphatase 2A, Ductal carcinoma in situ, Prognosis, Invasive ductal cancer

中图分类号: 

  • R737.9
[1] Huang Z, Wen W, Zheng Y, et al. Breast cancer incidence and mortality: trends over 40 years among women in Shanghai, China[J]. Ann Oncol, 2016, 27(6): 1129-1134.
[2] 庄婷, 薛梅, 房爱菊, 等. 黏蛋白(MUC1、MUC2、MUC5AC和MUC6)在乳腺浸润性导管癌中的表达及意义[J]. 山东大学学报(医学版), 2012, 50(5): 107-111. ZHUANG Ting, XUE Mei, FANG Aiju, et al. Expression of mucins(MUC1, MUC2, MUC5AC and MUC6)and their significance in invasive ductal breast carcinoma[J]. Journal of Shandong University(Health Sciences), 2012, 50(5): 107-111.
[3] 高永生, 王春健, 蔡淑萍, 等. Netrin-1在乳腺浸润性导管癌中的表达及与转移的相关性[J]. 山东大学学报(医学版), 2015, 53(7): 39-42. GAO Yongsheng, WANG Chunjian, CAI Shuping, et al. Expression of netrin-1 in invasive ductal breast cancer and its relationship with tumor metastasis [J]. Journal of Shandong University(Health Sciences), 2015, 53(7): 39-42.
[4] Sgroi DC. Preinvasive breast cancer [J]. Annu Rev Pathol, 2010,(5): 193-221.
[5] Tavassoli FA, Devilee P. Pathology and genetics: tumours of the breast and female genital organs [M]. Lyon, France, IARC Press, 2003.
[6] Junttila MR, Puustinen P, Niemel M, et al. CIP2A inhibits PP2A in human malignancies [J]. Cell, 2007, 130(1): 51-62.
[7] De P, Carlson J, Leyland-Jones B, et al. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A(CIP2A): an oncoprotein with many hands [J]. Oncotarget, 2014, 5(13): 4581-4602.
[8] Ventelä S, Sittig E, Mannermaa L, et al. CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance [J]. Oncotarget, 2015, 6(1): 144-158.
[9] Wiegering A, Pfann C, Uthe FW, et al. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression [J]. PLoS One, 2013, 8(10): 75292.
[10] Dong QZ, Wang Y, Dong XJ, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis [J]. Ann Surg Oncol, 2011, 18(3): 857-865.
[11] Liu J, Wang X, Zhou G, et al. Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein [J]. Gynecol Oncol, 2011, 122(2): 430-436.
[12] Yu HC, Chen HJ, Chang YL, et al. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma [J]. Biochem Pharmacol, 2013, 85(3): 356-366.
[13] Zhang W, Chen H, Chen Y, et al. Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1 [J]. Oncotarget, 2015, 6(7): 5253-5262.
[14] Laine A, Sihto H, Come C, et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1 [J]. Cancer Discov, 2013, 3(2): 182-197.
[15] Puustinen P, Jäättelä M. KIAA1524/CIP2A promotes cancer growth by coordinating the activities of MTORC1 and MYC [J]. Autophagy, 2014, 10(7): 1352-1354.
[16] Böckelman C, Hagström J, Mäkinen LK, et al. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer [J]. Br J Cancer, 2011, 104(12): 1890-1895.
[17] Chen JS, Wu BB, Bao HL, et al. Relationship between CIP2A expression, and prognosis and MDR-related proteins in patients with advanced gastric cancer [J]. Int J Clin Exp Pathol, 2015, 8(11): 15007-15012.
[18] Li W, Ge Z, Liu C, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells [J]. Clin Cancer Res, 2008, 14(12): 3722-3728.
[19] Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update [J]. Clin Oncol, 2013, 31(31): 3997-4013.
[20] Mommers EC, Leonhart AM, Falix F, et al. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade [J]. J Pathol, 2001, 194(3): 327-333.
[21] Niemelä M, Kauko O, Sihto H, et al. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes [J]. Oncogene, 2012, 31(39): 4266-4278.
[22] Côme C, Laine A, Chanrion M, et al. CIP2A is associated with human breast cancer aggressivity [J]. Clin Cancer Res, 2009, 15(16): 5092-5100.
[23] Kim JS, Kim EJ, Oh JS, et al. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1 [J]. Cancer Res, 2013, 73(22): 6667-6678.
[24] Pallai R, Bhaskar A, Barnett-Bernodat N, et al. Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells [J]. Tumour Biol, 2015, 36(8): 6383-6390.
[25] Böckelman C, Lassus H, Hemmes A, et al. Prognostic role of CIP2A expression in serous ovarian cancer [J]. Br J Cancer, 2011, 105(7): 989-995.
[26] Flørenes VA, Emilsen E, Dong HP, et al. Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma [J]. Cancer Med, 2015, 4(6): 903-913.
[1] 李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[2] 刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[3] 王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[4] 贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[5] 杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[6] 杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[7] 刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[8] 陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[9] 郭姝画,樊扬,田风,王传新,杜鲁涛,李培龙,郭兴,徐硕. 微原纤维相关蛋白3在调控胶质瘤干细胞间充质表型转化中的作用[J]. 山东大学学报 (医学版), 2024, 62(6): 9-16.
[10] 魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94.
[11] 刘春铖,刘晓晗,魏闫若雪,李梓绮,刘玉昆,赵然. 结直肠癌中含溴结构域蛋白9的亚细胞定位模式及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(4): 24-30.
[12] 杨雪彦,吴寅平,吕丽,赵泽华,马行宇,李凤彩,王凯,范玉琛. 单核细胞与淋巴细胞比值动态变化对慢加急性乙型肝炎肝衰竭预后的诊断价值[J]. 山东大学学报 (医学版), 2024, 62(3): 61-69.
[13] 刁玉洁,林琳,李文瑄,王洲洋,江蓓,胡迎迎,刘广义. NPR预测ANCA相关血管炎不良肾脏预后及其协同多因素优化模型[J]. 山东大学学报 (医学版), 2024, 62(2): 60-68.
[14] 宋兆录,董正璇,彭传真,黄彩娜,胡克清,黄永胜,阎磊. 肾透明细胞癌中预后相关RNA编辑位点的筛选[J]. 山东大学学报 (医学版), 2023, 61(9): 69-78.
[15] 刘艳,冷珊珊,夏晓娜,董昊,黄陈翠,孟祥水. 基于影像组学参数评估376例幕上自发性脑出血患者的功能状态[J]. 山东大学学报 (医学版), 2023, 61(5): 59-67.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发